Receipt date: 05/24/2006



HERSHKOVITZ & ASSOCIATES 1725 I STREET N.W. SUITE 300 WASHINGTON, DC 20006 703-323-9330

In re. Application of Appln. No. : Nicolae MANOLESCU et al Docke

: 10/567,842 : July 20, 2004 Docket No.:P02250 Group Art Unit: Unknown Examiner: Unknown

For: METHOD FOR IN VIVO DETERMINATION ON TESTED ANIMALS OF THE EFFICIENT CONCENTRATION OF DEUTERIUM DEPLETED WATER FOR CANCER THER APY

COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

Sir:

Filed

Transmitted herewith is an IDS in the above-captioned application.

- X Form PTO-1449
- X Copies of references cited

The fee has been calculated as shown below:

Claims After	No. of Claims	Present	Small Er	Entity Large Entity		ntity
Amendment	Previously Paid	Extra				
			Rate	Fee	Rate	Fee
*Total Claims:			x 25=	\$ 0	x 50=	\$
**Indep. Claims:			x 100=	\$ 0	x 200=	\$
Multiple Dependent Claims Presented			+180=	\$	+360=	\$
Extension Fees for 1 Month		60	\$	120	\$	
				\$		\$
			Total:	\$ 0	Total:	\$

^{*} If less than 20, write 20

__Please charge my Deposit Account No. 50-2929 in the amount of \$.

A Check in the amount of \$ __ to cover the necessary fee is included.

X The U.S. Patent and Trademark Office is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-2929:

X Any additional filing fees required under 37 C.F.R. 1.16.

Any patent application processing fees under 37 C.F.R. 1.17, including any required extension of time fees in any concurrent or future reply requiring a petition for extension of time for its timely submission (37 CFR 1.136/ja)(3).

May 24, 2006 Date Abraham Hershkovitz Reg. No. 45,294

^{**}If less than 3, write 3



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Nicolae MANOLESCU et al

Group Art Unit: Unknown

Appln. No.: 10/567,842

Examiner: Unknown

Filed : July 20, 2004

For

Confirmation No.: 7147

: METHOD FOR IN VIVO DETERMINATION ON TESTED ANIMALS
OF THE EFFICIENT CONCENTRATION OF DEUTERIUM DEPLETED

WATER FOR CANCER THERAPY

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure set forth in 37 CFR 1.56 and in accordance with the provisions of 37 CFR 1.97 and 1.98, the following information is brought to the attention of the Examiner for consideration during examination of the instant application.

Applicant submits herewith a copy of the International Search Report (in English) mailed on February 28, 2005 and conducted in International Application No. PCT/RO2004/000012 of which the instant application is the U.S. National stage. In particular, the International Examiner cited:

- Somlyai G et al: "The Biological Effects of Deuterium-Depleted Water, a Possible New Tool in Cancer Therapy";
- (2) WO 95/18545; this document is also cited beginning in paragraph [0003] of

P02250.A04

the present application;

- US 5,855,921 is cited beginning in paragraph [0009] of the present application;
- (4) RO 112422 is cited beginning in paragraph [0002] of the present application;
- (5) FR 2 552 324 is cited beginning in paragraph [0002] of the present application;
- PCT WO 96/33129 is cited beginning in paragraph [0002] of the present application;
- RU 2 182 562 is cited beginning in paragraph [0002] of the present application;
- (8) US 5,788,953 is cited beginning in paragraph [0003] of the present application;
- (9) WO 96/03996 is cited beginning in paragraph [0003] of the present application;
- (10) Billingham, R.E. et al., 1953 nature, 172, 603 is cited beginning in paragraph [0005] of the present application;
- (11) Miles, C.P., 1965, J Natl. cancer Inst. 34,103 is cited beginning in paragraph [0005] of the present application; and

P02250 A04

(12) Romanian Journal of Comparative Oncology, 4,295 is cited beginning in paragraph [0005] of the present application.

Copies of the above-listed documents (1), (2), (4)-(7), (9), (10) and (12) are enclosed herewith, as is a copy of the International Search Report and a completed copy of the PTO-1449 form listing these documents. Copies of documents (3) and (8) are not provided since they are U.S. patents readily available to the Examiner. A copy of document (11) is not yet available and will be provided as soon as it can be obtained. Accordingly, the Examiner is requested to consider these documents and to indicate such consideration by returning a signed and initialed copy of the PTO-1449 form as part of the next official communication.

Please charge any additional fees necessary for consideration of the papers filed herein and refund excess payments to Deposit Account No. 50-2929.

Questions related to this submission may be directed to the undersigned.

Respectfully submitted, Nicolae MANOLESCU

May 24, 2006 HERSHKOVITZ & ASSOCIATES 1725 I STREET, N.W. SUITE 300 WASHINGTON, DC 20006

(703) 323-9330 (703) 323-6617 (FAX) Abraham Hershkovitz Reg. No. 45,294 Receipt date: 05/24/2006

AA

RF

Substitute for form PTO-1449

(Use as many sheets as necessary)

US 5,788,953

WO 9633129

Complete if Known INFORMATION DISCLOSUR Opplication Number 10/567.842 Filing Date July 20, 2004 STATEMENT BY APPLICANT First Named Inventor Nicolae MANOLESCII Unknown

Unknown

Examiner Name

SOMLYAL

KOTAI

Sheet οf Attorney Docket Number 1 P02250 | 1 U.S. PATENT DOCUMENTS Examiner Cite Document Number **Publication Date** Name of Patentee or Pages, Columns, Lines, Initials* Nο MM-DD-YYYY Applicant of Cited Document Where Relevant Passages or Relevant Figures Number-Kind Code2 (if Appear known)

08/04/1998

US 5,855,921 01/05/1999 SOMLYAL AB FOREIGN PATENT DOCUMENTS Cite Foreign Patent Document Publication Date Name of Patentee or Pages, Columns, Initials* No. MM-DD-YYYY Applicant of Cited Document Lines, Where Relevant Passages Country Code3 -Number 4 or Relevant Figures Kind Code⁵ (if known) Appear BA FR 2552324 IONESCU 03/29/1985 RR RO 112422 09/30/1997 STEFANESCU et al BC RU 2182562 05/20/2002 SINJAK JU RD WO 96/03996 02/15/1996 BAUER BE WO 95/18545 07/13/1995 SOMLYAI

NON DATENT LITEDATURE DOCUMENTO

10/24/1996

			NON PATENT LITERATURE I					
	Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
		CA	Billingham, R.E. et al. transplantation 2003, 76, 1409-1412					
[CB	Miles, C.P., 1965, J Natl. cancer Inst. 34,103					
Cor	misel e	e Cal	Romanian Journal of Comparative Oncology 2001, 295-299					
		CD	SOMLYAI et al: "The Biological Effects of Deuterium-Depleted Water, a Possible New Tool in Cancer Therapy" J. Oncol. 1998, 30, 91-94					
	Examiner Signature		/Melissa Perreira/	Date Considered	09/28/2009			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional), 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3), 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document, 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.